• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Expert consortium begins study in South Africa to develop an optimized treatment for cryptococcal meningitis

Home > Press releases

Expert consortium begins study in South Africa to develop an optimized treatment for cryptococcal meningitis

Doctor with patient in hospital setting
Cape Town — 25 Feb 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

A consortium of leading scientists and institutions in Africa and Europe has launched a project with funding from the European & Developing Countries Clinical Trials Partnership (EDCTP) aimed at delivering an improved formulation of a lifesaving treatment for cryptococcal meningitis – one of the leading causes of death in people with advanced HIV.

About 180,000 people a year, mostly in African countries, die from cryptococcal meningitis, a fungal infection which invades the lining of the brain. People with advanced HIV are particularly susceptible to it because they have weakened immune systems. Of the 180,000 annual deaths from cryptococcal meningitis, 135,000 are in sub-Saharan Africa.

‘We are excited about collaborating with committed and outstanding research partners across two continents to develop a better adapted treatment for this devastating illness,’ said Carol Ruffell, project leader of the 5FC Sustained Release (SR) development programme and Head of the Southern Africa Office of the non-profit research organization, Drugs for Neglected Diseases initiative (DNDi), which is coordinating the consortium.

The consortium recently launched a Phase I study at FARMOVS, a clinical research facility in Bloemfontein, South Africa, to develop a new formulation of the existing treatment, known as flucytosine (5FC). This new sustained release formulation (5FC SR) would only need to be administered twice a day instead of four times a day, as it is the case now.

‘It would make a huge difference to give the patient flucytosine only twice a day, especially as we have so many patients to look after in our hospitals. It would help not having to administer the treatment in the middle of the night,’ said Ida Oliphant, a nurse who treats cryptococcal meningitis patients at Khayelitsha hospital in Cape Town. ‘Being able to take the treatment only every 12 hours would also encourage patients to complete the course once they are discharged from hospital.’

While undiagnosed and untreated fungal meningitis is fatal, over 70 percent of people can survive if they receive early, safe, and effective treatment with a combination of medicines including flucytosine.

‘I thought I was going to die when I had cryptococcal meningitis. The pain from terrible headaches was unbearable. Treatment gave me back my life and I no longer have any fear of dying. I’m so grateful. Treatment is the best thing I can ever advise to anyone. It saved my life,’ said Zikhona Mboto, a former cryptococcal meningitis patient.

The Phase I study will assess the comparative bioavailability of three candidate 5FC SR formulations in healthy study participants. The formulation is being developed so that it can be used as pellets which can be taken with water as well as via nasogastric tube. A Phase II study will follow in 2023 and 2024 in sites in Malawi and Tanzania, where cryptococcal meningitis patients will be enrolled in a randomized, controlled clinical trial to assess the 5FC SR formulation.

The consortium comprises a selected group of partners with an excellent track record of success delivering new tools and treatment strategies with an impact on public health: DNDi; FARMOVS; investigators from St George’s University of London; the National Institute for Medical Research (NIMR), Tanzania; the Lilongwe Medical Relief Fund Trust (LMRFT) in a partnership with the Kamuzu Central Hospital, Malawi; and the Luxembourg Institute of Health (LIH).

‘Cryptococcal meningitis is one of the unacceptably under-studied and under-funded HIV related comorbidities, especially in sub-Saharan Africa. To address this critical gap in such vulnerable populations, EDCTP provides funding to improve treatment and access to essential drugs, as well as diagnosis of cryptococcal infections, as an integral part of healthcare systems. We are very encouraged by the start of this very promising 5FC HIV-Crypto consortium,’ said Michael Makanga, Executive Director of European & Developing Countries Clinical Trials Partnership (EDCTP).

In tandem with the clinical trial work, the consortium will mobilize support for a combination of lifesaving treatments to be more widely available, particularly in African countries that are hard-hit by the disease.

Access to treatment for cryptococcal meningitis is urgently needed but is severely limited. The consortium will carry out focused work to support a strategy to increase access to the currently used immediate release formulation of flucytosine, and then, once developed, the new sustained release formulation. It will work with supporting partners, organizations, and the CryptoMAG advocacy group to get flucytosine registered in more African countries, expand access to people who need it, and save lives.

About EDCTP

The European & Developing Countries Clinical Trials Partnership (EDCTP) funds clinical research for medical tools to detect, treat and prevent poverty-related infectious diseases in sub-Saharan Africa. The 5FC Sustained Release project is part of the EDCTP2 programme supported by the European Union (grant number RIA2018CO-2516).

About the EDCTP Consortium partners

DNDi is an international not-for-profit research and development organization which discovers and develops new treatments for neglected patients. DNDi has delivered nine treatments since its inception in 2003.

FARMOVS is a full-service clinical research organization in Bloemfontein, South Africa. It has conducted over 3,000 clinical trials that have facilitated the registration of pharmaceutical products and has submitted to a variety of regulatory authorities, including the FDA (USA), EMA (Europe), WHO, and MHRA (UK).

The investigators from St George’s University of London, National Institute for Medical Research (NIMR), Tanzania, and the Lilongwe Medical Relief Fund Trust (LMRFT) in partnership with the Kamuzu Central Hospital, Malawi, have designed and implemented a series of Phase II to IV trials that have transformed the treatment of cryptococcal meningitis and led to updated WHO treatment guidelines.

The Luxembourg Institute of Health (LIH) is a biomedical research centre whose main mission is to support translational research. Its Competence Centre for Methodology and Statistics is a well-known centre for data management and statistics in global health. LIH involvement is supported by the National Research Fund from Luxembourg (INTER/EDCTP/19/13991296/5FC HIV-Crypto).

Media contacts

Cape Town, South Africa: Kim Cloete
kcloete@extern.gardp.org
+27 82 4150736

Geneva, Switzerland: Frédéric Ojardias
fojardias@dndi.org
+41 79 431 62 16

EDCTP: Ilona van den Brink
media@edctp.org

Photo credit: Karin Schermbrucker-DNDi

Translational research Cryptococcal meningitis South Africa

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY